Here are the latest new cancer drugs approved by the Food and Drug Administration:

  • Aucatxyl (obecabtagene autoleucel), a new CAR-T therapy for acute lymphoblastic leukemia

  • Bizengri (zenocutuzumab), a bispecific antibody for lung cancer and pancreatic cancer

  • Datroway (datopotamab deruxtecan), an antibody-drug conjugate for HER2-negative metastatic breast cancer

  • Enhertu (fam-trastuzumab deruxtecan), an antibody-drug conjugate for HER2-ultralow metastatic breast cancer

  • Ensacove (ensartinib), a targeted therapy for ALK-positive non-small-cell lung cancer

  • Itovebi (inavolisib), a PI3K-pathway inhibitor for metastatic breast cancer

  • Opdivo Qvantig, an injectable formulation of the PD-1 checkpoint inhibitor nivolumab

  • Revuforj (revumenib), the first menin inhibitor for relapsed or refractory acute leukemia

  • Unloxcyt (cosibelimab), a PD-L1 checkpoint inhibitor for cutaneous squamous cell carcinoma

  • Vyloy (zolbetuximab), a claudin 18.2 monoclonal antibody, for HER2-negative stomach cancer

  • Ziihera (zanidatamab), a bispecific antibody for HER2-positive biliary tract cancer